SOUTH EASTON, Mass, - (http://www.financialnewsmedia.com News Alert) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced it has entered into a two-year collaboration with the Institute of Bioinformatics ("IOB") in Bangalore, India. The IOB is one of the most prestigious not-for-profit scientific research centers in India, and one of the more highly regarded proteomic research organizations worldwide. The IOB staff, which includes dozens of scientists with advanced degrees, have published several hundred scientific papers over the past decade, many with a strong focus in the areas of proteomics, genomics, and metabolomics.
Dr. Pandey commented: "The preparation of samples for analysis is a crucial step in all research studies worldwide aimed at finding biomarkers for the detection, control, prevention, and/or cure of human diseases and disorders. The IOB has modern, well-equipped facilities; however, we are well aware that the quality of results from our state-of-the-art instruments depends to a great extent on the quality and uniformity of the preparation of the samples being analyzed. Consequently, we are always searching for better, higher quality sample preparation methods that can help us process a diverse set of samples ranging from tissue biopsies to bacterial extracts. This is how we met our colleagues at PBI, learned about the power of their PCT platform, and subsequently purchased our first PCT instrument."
Dr. Harsha Gowda, head of the proteomics program at the IOB, said: "For much of the past year, we have evaluated the PCT platform in our laboratories. We have used it extensively for preparing protein samples from paraffin-embedded biopsy tissue sections for mass spectrometry-based analysis. Early results from this very robust platform are encouraging and exciting. Consequently, we were pleased to enter into a formal, two-year collaboration with our colleagues at PBI. During this time, we will use the PCT platform as the front-end, sample preparation method to many universally-used analytical instruments, such as mass spectrometers and third generation DNA sequencers. Based on our results to date, we believe the PCT platform may prove to be advantageous as a sample preparation method to researchers worldwide, and perhaps also necessary for many other applications as well."
Mr. Richard T. Schumacher, President and CEO of PBI, said: "We are honored to work with such a worldwide respected scientist as Dr. Pandey. We are further honored to collaborate with Dr. Gowda and his colleagues at the IOB. We believe there are as many as 500,000 researchers around the world working with biological samples, many of whom use the same kinds of instruments (e.g., mass spectrometers, DNA sequencers, HPLCs, etc.) as those used by scientists at the IOB. These researchers are potential future users of the PCT platform. We believe the results generated at the IOB will help show the clear advantages offered by the PCT platform when this powerful, patented technology is used in the search for biomarkers. We believe that such data, coming from a research institute with the worldwide reputation of the IOB, could have the profound effect of helping to change the PCT platform from a "want to have" to a "have to have" sample preparation system for biological research laboratories, in India and around the world."
About the Institute of Bioinformatics
The Institute of Bioinformatics is a not-for-profit research organization engaged in biomedical research. Located in Bangalore, India, it was established in May 2002. Bangalore is a prime center for research and development and is the hub of both information technology and biotechnology in India. The Institute of Bioinformatics is a multidisciplinary systems biology research institute where scientists combine cutting-edge experimental methods in genomics, proteomics, and metabolomics with advanced computational biology, to investigate biomarkers and therapeutic targets of various diseases, including cancer.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter
Investor Contacts:
Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
Nathan P. Lawrence, Ph.D. VP of Marketing and Sales
+1(508) 230-1828 (T)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-and-the-institute-of-bioinformatics-announce-comprehensive-two-year-collaboration-300133456.html
SOURCE Pressure BioSciences, Inc.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG was compensated two thousand five hundred dollars for Pressure BioSciences, Inc. news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Pressure BioSciences, Inc.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
